Veriti Management LLC raised its position in Grifols, S.A. (NASDAQ:GRFS – Get Rating) by 98.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,546 shares of the biotechnology company’s stock after purchasing an additional 37,047 shares during the quarter. Veriti Management LLC’s holdings in Grifols were worth $871,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the business. Capital World Investors lifted its holdings in shares of Grifols by 14.9% in the 4th quarter. Capital World Investors now owns 14,907,138 shares of the biotechnology company’s stock worth $167,407,000 after acquiring an additional 1,932,123 shares during the last quarter. Black Creek Investment Management Inc. lifted its holdings in shares of Grifols by 9.3% in the 4th quarter. Black Creek Investment Management Inc. now owns 6,025,807 shares of the biotechnology company’s stock worth $67,670,000 after acquiring an additional 512,509 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Grifols by 7.1% in the 3rd quarter. Janus Henderson Group PLC now owns 4,754,682 shares of the biotechnology company’s stock worth $69,513,000 after acquiring an additional 315,440 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of Grifols by 6.0% in the 4th quarter. First Trust Advisors LP now owns 4,141,459 shares of the biotechnology company’s stock worth $46,509,000 after acquiring an additional 235,120 shares during the last quarter. Finally, Flat Footed LLC acquired a new position in shares of Grifols in the 4th quarter worth approximately $12,983,000. Institutional investors own 14.71% of the company’s stock.
Several equities analysts have recently commented on the stock. Morgan Stanley assumed coverage on shares of Grifols in a report on Friday, April 8th. They issued an “equal weight” rating on the stock. Berenberg Bank dropped their price target on shares of Grifols from €21.60 ($22.74) to €21.40 ($22.53) in a research note on Thursday, March 3rd. Finally, StockNews.com assumed coverage on Grifols in a research report on Thursday, March 31st. They set a “hold” rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Grifols presently has an average rating of “Hold” and a consensus price target of $16.20.
Grifols Profile (Get Rating)
Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.
- Get a free copy of the StockNews.com research report on Grifols (GRFS)
- Ciena Stock Giving Window of Opportunity
- Zai Lab Stock Has Fallen to Value Levels
- Are These Cheap Copper Stocks Right For Your Portfolio?
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.